
Fosun International Receives the “ESG & Sustainability Award” and Two Other Prestigious Honors from Global Banking and Finance Review
How did your country report this? Share your view in the comments.
Diverging Reports Breakdown
Fosun International Receives the “ESG & Sustainability Award” and Two Other Prestigious Honors from Global Banking and Finance Review
Fosun International Limited (HKEX stock code: 00656) was recently notified by the renowned British finance magazine, Global Banking and Finance Review, that it has received three awards. Fosun remains committed to its core businesses. By leveraging its increasingly sophisticated global business presence, it has operated responsibly across more than 35 countries and regions. It has been making unremitting efforts in the fields of global emergency relief, rural revitalization, healthcare, youth entrepreneurship, education, community development and culture & art, etc. to create social value. It fully supports the ten principles of the UN Global Compact on human rights, labor, environment and anti-corruption, and has deeply integrated these principles into its “Create IMPACT” sustainable development strategy and code of conduct. This makes it the first and only early-stage drug approved for the first-line treatment of lung cancer (ES-CCL-1) in the European Union in early 2025. Thanks to the long-term accumulated technology innovation capabilities, Henlius’ innovative drug, HSIZHulimang (an anti-PD-1 monoclonal antibody), was approved for European marketing in the early stage.
In recognition of these efforts, the magazine honored Fosun International with three prestigious awards in ESG and sustainability, corporate social responsibility, and branding. These accolades not only acknowledge the growth potential of Fosun’s core industries but also reaffirm the Company’s dedication to advancing ESG-driven sustainable development.
Global Banking and Finance Review highlighted that, after more than 30 years of development, Fosun has evolved into a global innovation-driven consumer group. As a global large-scale private enterprise, Fosun has pursued a core business-focused strategy, embraced innovation, and advanced its globalization efforts, leading to steady business growth. While enhancing its operations, Fosun has also strengthened its sustainable development management, actively fulfilling corporate social responsibility, improving ESG performance, and leveraging the resources and advantages of its global industrial ecosystem to contribute to a better world.
HONG KONG, June 11, 2025 /PRNewswire/ — Fosun International Limited (HKEX stock code: 00656) was recently notified by the renowned British finance magazine, Global Banking and Finance Review , that it has received three awards: “ESG & Sustainability Awards – Best Sustainable Development Company Asia 2025”, “CSR Awards – Best CSR Company Asia 2025”, and “Brand of the Year Awards – Holding Group Brand of the Year Asia 2025”. These accolades underscore the market’s recognition of Fosun’s exceptional performance in ESG strategy, corporate governance, social responsibility, environmental protection, information disclosure, and stakeholder engagement.
Story Continues
Advancing Global Sustainable Development with Outstanding ESG Performance
Fosun remains committed to its core businesses. By leveraging its increasingly sophisticated global business presence, it has operated responsibly across more than 35 countries and regions, actively contributing to public welfare and creating sustainable value worldwide. Fosun has long been dedicated to philanthropy projects in areas such as rural revitalization, healthcare, educational equity, community construction, culture and art, significantly expanding its impact across global communities and striving to build a more responsible, inclusive and sustainable future.
As a responsible global citizen, Fosun officially joined the United Nations Global Compact (“UN Global Compact”) in 2014. It fully supports the ten principles of the UN Global Compact on human rights, labor, environment and anti-corruption, and has deeply integrated these principles into its “Create IMPACT” sustainable development strategy and code of conduct. Over the past year, despite the global environmental, social and economic uncertainties, Fosun remained committed to sustainable development, diligently upholding its long-term commitments in key areas of sustainable development, and achieving good results. Fosun International maintained an MSCI ESG rating of AA, achieved an HSI ESG rating of AA-, ranked in the top 5% among global peers in latest S&P Global’s Corporate Sustainability Assessment (CSA), was included in S&P Global’s Sustainability Yearbook 2025, and was selected as the top 1% in S&P Global’s Sustainability Yearbook 2025 (China Edition).
Fosun for Good: Giving Back to Society
In order to better promote the fulfillment and implementation of corporate social responsibility, Fosun Foundation was established in 2012. It has been making unremitting efforts in the fields of global emergency relief, rural revitalization, healthcare, youth entrepreneurship, education, community development and culture & art, etc. to create social value. Among these initiatives, the Rural Doctors Program has supported 25,000 rural doctors and benefited 3 million rural families since its launch in 2017. Moreover, the “Rural Doctors Program Empowering Rural Medical Services” was included in the “20 Cases of Private Sector’s Sustainable Development in China for 20 Years” Report of the UN Global Compact.
Fosun adheres to the innovation-driven strategy and actively facilitates its businesses to achieve innovative results so as to make greater contributions to society. Thanks to the long-term accumulated technology innovation capabilities, Fosun has continued to realize the “world’s first” and “China’s first” achievements. Henlius’ innovative drug, HANSIZHUANG (serplulimab injection), an anti-PD-1 monoclonal antibody, was approved for marketing in the European Union in early 2025. This milestone makes it the first and only PD-1 innovative drug approved for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in the European Union. As of the end of 2024, Fosun Pharma’s independently developed artesunate for injection had saved more than 80 million severe malaria patients worldwide, with more than 400 million doses supplied globally.
Regarding youth entrepreneurship and development, under the principle of “Innovation and People-oriented Development”, Fosun Foundation, in collaboration with Fidelidade and Portugal’s healthcare group Luz Saúde, launched the sustainable innovation project “Protechting Open Innovation Program” in early 2016. Since 2018, Protechting has incubated 40 pilot projects and led to 5 commercial collaborations. On 9 April 2025, the 7th Protechting Open Innovation Program took place in Lisbon, the capital of Portugal, where the top four finalists were announced. In May 2025, these four teams visited Shanghai, Macau, Shenzhen, and Hong Kong for exchanges and roadshows, while also seeking potential business collaboration opportunities. Over the past seven years, Protechting has expanded from Portugal to Europe and now to China and beyond, becoming an international platform for technology innovation exchange that connects young people from different cultures and continents.
Looking ahead, Fosun remains dedicated to advancing its social responsibility through innovation and responsible global operations. Guided by its “Create IMPACT” sustainable development strategy, Fosun will intensify its efforts to build a more responsible, inclusive and sustainable future.
Cision
View original content:https://www.prnewswire.com/news-releases/fosun-international-receives-the-esg–sustainability-award-and-two-other-prestigious-honors-from-global-banking-and-finance-review-302478673.html
SOURCE Fosun
Source: https://finance.yahoo.com/news/fosun-international-receives-esg-sustainability-052500466.html